{
    "\nDESCRIPTION\n": "Timolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.\nTimolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:Its molecular formula is C13H24N4O3S\u2022C4H4O4, and its structural formula is:Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.Timolol maleate ophthalmic solution is supplied in two formulations: timolol maleate ophthalmic solution, which contains the preservative benzalkonium chloride; and timolol maleate ophthalmic solution, the preservative-free formulation.Preservative-free\u00a0timolol maleateophthalmic solution, USP is\u00a0supplied\u00a0in a single-dose vial, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in one dosage strength. \u00a0The pH of the solution is approximately 6.8 to 7.2, and the osmolarity is 252 to 328 mOsm. Each mL of preservative-free timolol maleateophthalmic solution USP, 0.5%\u00a0contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients:dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate (dihydrate), sodium hydroxide to adjust pH, and water for injection.",
    "CLINICAL PHARMACOLOGY": "MechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.\nMechanismofActionTimolol maleate\u00a0 is a beta1and\u00a0 beta2(non-selective)\u00a0 adrenergic receptor blocking\u00a0 agent\u00a0that\u00a0does not\u00a0 have\u00a0 significant\u00a0 intrinsic\u00a0sympathomimetic, direct\u00a0 myocardial depressant,\u00a0or\u00a0local\u00a0anesthetic\u00a0(membrane-stabilizing)\u00a0activity.Beta-adrenergic receptor blockade reduces\u00a0cardiac output \u00a0in\u00a0 both\u00a0healthy subjects and\u00a0patients with\u00a0heart\u00a0 disease. In patients with severe\u00a0impairment of myocardial function,\u00a0beta-adrenergic\u00a0receptor blockade may\u00a0inhibit the\u00a0stimulatory\u00a0effect of the\u00a0sympathetic\u00a0nervous\u00a0system necessary\u00a0to maintain\u00a0adequate cardiac\u00a0function.Beta-adrenergic receptor blockade\u00a0 in the bronchi\u00a0 and\u00a0 bronchioles results in increased\u00a0airway\u00a0resistance from\u00a0unopposed\u00a0parasympathetic activity. Such\u00a0an effect in\u00a0patients\u00a0with asthma\u00a0 or\u00a0 other bronchospastic conditions\u00a0 is\u00a0 potentially\u00a0 dangerous.Timolol maleate\u00a0ophthalmic solution,\u00a0when applied topically\u00a0on the eye, has\u00a0the\u00a0action\u00a0 of reducing elevated as\u00a0well\u00a0 as\u00a0 normal\u00a0 intraocular\u00a0 pressure,\u00a0 whether\u00a0 or\u00a0 not\u00a0accompanied by\u00a0 glaucoma. Elevated\u00a0intraocular pressure is\u00a0a major risk\u00a0factor\u00a0 in the\u00a0pathogenesis of\u00a0 glaucomatous\u00a0visual\u00a0field loss. The higher the\u00a0level\u00a0 of\u00a0 intraocular\u00a0pressure,\u00a0the greater\u00a0 the\u00a0 likelihood\u00a0 of\u00a0 glaucomatous\u00a0 visual\u00a0 field\u00a0 loss\u00a0 and\u00a0 optic\u00a0 nerve\u00a0 damage.The\u00a0onset\u00a0of\u00a0reduction\u00a0in intraocular\u00a0pressure\u00a0following\u00a0administration\u00a0of timolol\u00a0maleate ophthalmic solution\u00a0can\u00a0usually be detected\u00a0within \u00a0one-half hour after\u00a0a\u00a0single\u00a0dose. The\u00a0maximum effect usually occurs\u00a0in one to\u00a0two hours, and\u00a0 significant\u00a0lowering\u00a0of\u00a0 intraocular pressure can be maintained for periods as\u00a0 long\u00a0 as 24\u00a0 hours\u00a0 with\u00a0a\u00a0single dose. Repeated\u00a0observations\u00a0 over\u00a0a period of\u00a0 one year indicate that\u00a0the\u00a0intraocular\u00a0pressure-lowering\u00a0effect\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0is well maintained.The\u00a0precise\u00a0mechanism of\u00a0the\u00a0ocular\u00a0hypotensive\u00a0action\u00a0of\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0is\u00a0not\u00a0 clearly\u00a0 established at this time.\u00a0Tonography\u00a0 and\u00a0fluorophotometry studies in man suggest that its predominant action may\u00a0be\u00a0related\u00a0to\u00a0reduced\u00a0aqueous\u00a0 formation. However,\u00a0 in some\u00a0studies a\u00a0slight increase in outflow\u00a0facility was \u00a0also observed.PharmacokineticsIn\u00a0a\u00a0study\u00a0of\u00a0 plasma drug concentration\u00a0in six\u00a0subjects, the\u00a0 systemic exposure to\u00a0timolol\u00a0was\u00a0determined following twice\u00a0daily administration of\u00a0timolol maleateophthalmic solution\u00a00.5%.\u00a0The\u00a0mean peak\u00a0plasma concentration following\u00a0 morning\u00a0 dosing\u00a0 was\u00a0 0.46\u00a0 ng/mL\u00a0 and\u00a0 following\u00a0 afternoon\u00a0dosing was\u00a0 0.35\u00a0 ng/mL.ClinicalStudiesIn\u00a0controlled\u00a0multiclinic\u00a0studies\u00a0 in\u00a0 patients\u00a0 with\u00a0 untreated intraocular pressures\u00a0of\u00a0 22\u00a0mmHg\u00a0or greater,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution, 0.25% or\u00a00.5%\u00a0administered twice\u00a0a day produced a greater reduction\u00a0 in\u00a0 intraocular pressure than 1,\u00a0 2,\u00a03, or 4%\u00a0 pilocarpine\u00a0solution administered four\u00a0times\u00a0a day or 0.5,\u00a0 1, or 2%\u00a0 epinephrine\u00a0hydrochloride solution\u00a0 administered\u00a0twice\u00a0a day.In\u00a0these\u00a0studies,\u00a0timolol maleate\u00a0ophthalmic\u00a0solution\u00a0was generally well\u00a0tolerated\u00a0and\u00a0 produced\u00a0 fewer\u00a0 and\u00a0 less severe side effects than either pilocarpine or\u00a0epinephrine.\u00a0A slight\u00a0reduction\u00a0 of resting\u00a0heart rate\u00a0in\u00a0some\u00a0patients\u00a0 receiving\u00a0timolol\u00a0maleate\u00a0ophthalmic solution\u00a0(mean\u00a0reduction\u00a02.9\u00a0beats/minute\u00a0standard\u00a0 deviation\u00a0 10.2)\u00a0 was\u00a0 observed.",
    "INDICATIONS AND USAGE": "Preservative-free\u00a0timolol\u00a0maleateophthalmic solution\u00a0is\u00a0indicated\u00a0in\u00a0the\u00a0treatment\u00a0of elevated\u00a0intraocular\u00a0 pressure\u00a0 in\u00a0 patients\u00a0 with\u00a0 ocular\u00a0 hypertension\u00a0 or\u00a0 open-angle\u00a0 glaucoma.Preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0be\u00a0used when a\u00a0patient is\u00a0sensitive\u00a0to\u00a0the\u00a0preservative\u00a0in\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution,\u00a0benzalkonium\u00a0chloride, or\u00a0 when\u00a0 use\u00a0 of a\u00a0preservative-free topical medication\u00a0 is\u00a0 advisable.\nPreservative-free\u00a0timolol\u00a0maleateophthalmic solution\u00a0is\u00a0indicated\u00a0in\u00a0the\u00a0treatment\u00a0of elevated\u00a0intraocular\u00a0 pressure\u00a0 in\u00a0 patients\u00a0 with\u00a0 ocular\u00a0 hypertension\u00a0 or\u00a0 open-angle\u00a0 glaucoma.Preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0be\u00a0used when a\u00a0patient is\u00a0sensitive\u00a0to\u00a0the\u00a0preservative\u00a0in\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution,\u00a0benzalkonium\u00a0chloride, or\u00a0 when\u00a0 use\u00a0 of a\u00a0preservative-free topical medication\u00a0 is\u00a0 advisable.\nPreservative-free\u00a0timolol\u00a0maleateophthalmic solution\u00a0is\u00a0indicated\u00a0in\u00a0the\u00a0treatment\u00a0of elevated\u00a0intraocular\u00a0 pressure\u00a0 in\u00a0 patients\u00a0 with\u00a0 ocular\u00a0 hypertension\u00a0 or\u00a0 open-angle\u00a0 glaucoma.Preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0be\u00a0used when a\u00a0patient is\u00a0sensitive\u00a0to\u00a0the\u00a0preservative\u00a0in\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution,\u00a0benzalkonium\u00a0chloride, or\u00a0 when\u00a0 use\u00a0 of a\u00a0preservative-free topical medication\u00a0 is\u00a0 advisable.\nPreservative-free\u00a0timolol\u00a0maleateophthalmic solution\u00a0is\u00a0indicated\u00a0in\u00a0the\u00a0treatment\u00a0of elevated\u00a0intraocular\u00a0 pressure\u00a0 in\u00a0 patients\u00a0 with\u00a0 ocular\u00a0 hypertension\u00a0 or\u00a0 open-angle\u00a0 glaucoma.Preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0be\u00a0used when a\u00a0patient is\u00a0sensitive\u00a0to\u00a0the\u00a0preservative\u00a0in\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution,\u00a0benzalkonium\u00a0chloride, or\u00a0 when\u00a0 use\u00a0 of a\u00a0preservative-free topical medication\u00a0 is\u00a0 advisable.\nPreservative-free\u00a0timolol\u00a0maleateophthalmic solution\u00a0is\u00a0indicated\u00a0in\u00a0the\u00a0treatment\u00a0of elevated\u00a0intraocular\u00a0 pressure\u00a0 in\u00a0 patients\u00a0 with\u00a0 ocular\u00a0 hypertension\u00a0 or\u00a0 open-angle\u00a0 glaucoma.Preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0be\u00a0used when a\u00a0patient is\u00a0sensitive\u00a0to\u00a0the\u00a0preservative\u00a0in\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution,\u00a0benzalkonium\u00a0chloride, or\u00a0 when\u00a0 use\u00a0 of a\u00a0preservative-free topical medication\u00a0 is\u00a0 advisable.\nPreservative-free\u00a0timolol\u00a0maleateophthalmic solution\u00a0is\u00a0indicated\u00a0in\u00a0the\u00a0treatment\u00a0of elevated\u00a0intraocular\u00a0 pressure\u00a0 in\u00a0 patients\u00a0 with\u00a0 ocular\u00a0 hypertension\u00a0 or\u00a0 open-angle\u00a0 glaucoma.Preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0be\u00a0used when a\u00a0patient is\u00a0sensitive\u00a0to\u00a0the\u00a0preservative\u00a0in\u00a0timolol\u00a0maleate\u00a0ophthalmic\u00a0solution,\u00a0benzalkonium\u00a0chloride, or\u00a0 when\u00a0 use\u00a0 of a\u00a0preservative-free topical medication\u00a0 is\u00a0 advisable.",
    "CONTRAINDICATIONS": "Preservative-free timolol maleateophthalmic solution\u00a0is contraindicated\u00a0in\u00a0patients\u00a0with\u00a0(1)\u00a0bronchial asthma; (2)\u00a0a history\u00a0 of\u00a0 bronchial\u00a0 asthma; (3)\u00a0severe\u00a0 chronic\u00a0 obstructive\u00a0pulmonary\u00a0disease(see WARNINGS); (4)\u00a0sinus bradycardia;\u00a0(5)\u00a0second or third\u00a0degree\u00a0atrioventricular\u00a0block;\u00a0(6)\u00a0overt\u00a0cardiac failure(see WARNINGS);\u00a0(7)\u00a0cardiogenic shock;\u00a0or\u00a0(8)\u00a0hypersensitivity to\u00a0any\u00a0component\u00a0of this\u00a0product.\nPreservative-free timolol maleateophthalmic solution\u00a0is contraindicated\u00a0in\u00a0patients\u00a0with\u00a0(1)\u00a0bronchial asthma; (2)\u00a0a history\u00a0 of\u00a0 bronchial\u00a0 asthma; (3)\u00a0severe\u00a0 chronic\u00a0 obstructive\u00a0pulmonary\u00a0disease(see WARNINGS); (4)\u00a0sinus bradycardia;\u00a0(5)\u00a0second or third\u00a0degree\u00a0atrioventricular\u00a0block;\u00a0(6)\u00a0overt\u00a0cardiac failure(see WARNINGS);\u00a0(7)\u00a0cardiogenic shock;\u00a0or\u00a0(8)\u00a0hypersensitivity to\u00a0any\u00a0component\u00a0of this\u00a0product.\nPreservative-free timolol maleateophthalmic solution\u00a0is contraindicated\u00a0in\u00a0patients\u00a0with\u00a0(1)\u00a0bronchial asthma; (2)\u00a0a history\u00a0 of\u00a0 bronchial\u00a0 asthma; (3)\u00a0severe\u00a0 chronic\u00a0 obstructive\u00a0pulmonary\u00a0disease(see WARNINGS); (4)\u00a0sinus bradycardia;\u00a0(5)\u00a0second or third\u00a0degree\u00a0atrioventricular\u00a0block;\u00a0(6)\u00a0overt\u00a0cardiac failure(see WARNINGS);\u00a0(7)\u00a0cardiogenic shock;\u00a0or\u00a0(8)\u00a0hypersensitivity to\u00a0any\u00a0component\u00a0of this\u00a0product.\nPreservative-free timolol maleateophthalmic solution\u00a0is contraindicated\u00a0in\u00a0patients\u00a0with\u00a0(1)\u00a0bronchial asthma; (2)\u00a0a history\u00a0 of\u00a0 bronchial\u00a0 asthma; (3)\u00a0severe\u00a0 chronic\u00a0 obstructive\u00a0pulmonary\u00a0disease(see WARNINGS); (4)\u00a0sinus bradycardia;\u00a0(5)\u00a0second or third\u00a0degree\u00a0atrioventricular\u00a0block;\u00a0(6)\u00a0overt\u00a0cardiac failure(see WARNINGS);\u00a0(7)\u00a0cardiogenic shock;\u00a0or\u00a0(8)\u00a0hypersensitivity to\u00a0any\u00a0component\u00a0of this\u00a0product.",
    "WARNINGS": "As with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.\nAs with many topically\u00a0 applied ophthalmic drugs, this\u00a0drug\u00a0 is\u00a0 absorbed systemically.The\u00a0same\u00a0adverse\u00a0reactions\u00a0found\u00a0with\u00a0systemic\u00a0administration\u00a0of\u00a0beta-adrenergic \u00a0blocking\u00a0agents\u00a0may\u00a0occur\u00a0with\u00a0topical\u00a0administration.\u00a0For\u00a0example, severe\u00a0respiratory\u00a0reactions\u00a0and\u00a0cardiac\u00a0reactions,\u00a0including\u00a0death\u00a0due\u00a0to\u00a0bronchospasm\u00a0in\u00a0patients\u00a0with\u00a0asthma,\u00a0and\u00a0rarely\u00a0death\u00a0in\u00a0association\u00a0with\u00a0cardiac\u00a0failure,\u00a0have\u00a0been\u00a0reported\u00a0following\u00a0systemic\u00a0or\u00a0ophthalmic\u00a0administration\u00a0of\u00a0timolol\u00a0maleate\u00a0(see CONTRAINDICATIONS).CardiacFailureSympathetic\u00a0stimulation may be essential for support of\u00a0 the circulation\u00a0in\u00a0 individuals\u00a0with diminished myocardial\u00a0contractility, and its\u00a0inhibition by beta-adrenergic receptor\u00a0blockade may precipitate more\u00a0severe\u00a0failure.In\u00a0Patients\u00a0without\u00a0a\u00a0History\u00a0 of Cardiac Failurecontinued\u00a0 depression\u00a0of the\u00a0myocardium\u00a0with beta-blocking agents\u00a0 over a period of time\u00a0can,\u00a0in some\u00a0cases,\u00a0lead to\u00a0cardiac\u00a0failure.\u00a0At\u00a0the\u00a0first\u00a0sign\u00a0or\u00a0symptom\u00a0of\u00a0cardiac\u00a0failure,\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0should be\u00a0 discontinued.Obstructive Pulmonary\u00a0 DiseasePatients\u00a0with chronic obstructive\u00a0 pulmonary disease (e.g., chronic bronchitis,\u00a0emphysema)\u00a0of\u00a0mild\u00a0 or moderate severity, bronchospastic\u00a0disease,\u00a0 or\u00a0 a history of\u00a0bronchospastic disease (other than\u00a0 bronchial\u00a0 asthma\u00a0 or a history of\u00a0 bronchial asthma,\u00a0in\u00a0which\u00a0timolol maleateophthalmic solution\u00a0is\u00a0contraindicated(see CONTRAINDICATIONS))should,\u00a0in\u00a0general,\u00a0not\u00a0receive\u00a0beta-blockers,\u00a0including\u00a0preservative-free timolol maleateophthalmic solution.Major SurgeryThe\u00a0necessity or\u00a0 desirability of\u00a0 withdrawal\u00a0 of beta-adrenergic blocking\u00a0 agents prior to\u00a0major\u00a0surgery\u00a0 is controversial.\u00a0Beta-adrenergic\u00a0\u00a0 receptor blockade impairs\u00a0the ability of\u00a0the\u00a0heart to\u00a0respond to beta-adrenergically mediated reflex\u00a0stimuli.\u00a0This\u00a0may augment\u00a0the\u00a0risk of\u00a0 general anesthesia in\u00a0surgical procedures. Some patients receiving beta-adrenergic\u00a0receptor blocking agents\u00a0 have experienced protracted severe hypotension\u00a0during\u00a0anesthesia. Difficulty in restarting and maintaining the heartbeat has also been\u00a0reported.\u00a0For\u00a0these reasons,\u00a0in\u00a0\u00a0\u00a0patients\u00a0 undergoing elective\u00a0surgery,\u00a0some\u00a0authorities\u00a0recommend\u00a0gradual\u00a0withdrawal of beta-adrenergic receptor blocking agents.If\u00a0necessary during\u00a0surgery,\u00a0the\u00a0effects of beta-adrenergic\u00a0blocking agents\u00a0may\u00a0be\u00a0reversed\u00a0by sufficient doses\u00a0 of\u00a0 adrenergic\u00a0 agonists.DiabetesMellitusBeta-adrenergic blocking agents\u00a0 should\u00a0 be\u00a0 administered\u00a0with caution\u00a0in patients subject\u00a0to\u00a0spontaneous\u00a0 hypoglycemia\u00a0or to\u00a0diabetic\u00a0 patients (especially\u00a0those\u00a0with\u00a0 labile\u00a0diabetes) who\u00a0 are receiving\u00a0insulin or\u00a0 oral\u00a0 hypoglycemic agents.\u00a0 Beta-adrenergic\u00a0receptor\u00a0blocking\u00a0 agents may\u00a0mask\u00a0the\u00a0 signs\u00a0 and symptoms\u00a0of\u00a0 acute\u00a0 hypoglycemia.ThyrotoxicosisBeta-adrenergic blocking\u00a0agents may\u00a0mask\u00a0certain\u00a0clinical signs (e.g.,\u00a0tachycardia)\u00a0of\u00a0hyperthyroidism. Patients\u00a0suspected of\u00a0 developing thyrotoxicosis should be managed carefully\u00a0to\u00a0avoid abrupt withdrawal of beta-adrenergic blocking\u00a0agents that\u00a0might\u00a0precipitate\u00a0a\u00a0thyroid\u00a0storm.",
    "PRECAUTIONS": "GeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.\nGeneralBecause\u00a0of\u00a0potential effects of\u00a0beta-adrenergic blocking\u00a0agents on blood pressure and\u00a0pulse,\u00a0these agents should be\u00a0 used with caution in patients\u00a0 with cerebrovascular\u00a0insufficiency. If\u00a0signs or symptoms suggesting reduced\u00a0cerebral\u00a0blood flow develop\u00a0following\u00a0initiation\u00a0of\u00a0therapy\u00a0with\u00a0preservative-free \u00a0timolol maleateophthalmic solution, alternative\u00a0therapy should\u00a0be\u00a0considered.Choroidal detachment\u00a0after\u00a0filtration procedures\u00a0has been reported\u00a0with the\u00a0administration\u00a0of aqueous\u00a0suppressant\u00a0therapy\u00a0(e.g., timolol).Angle-closure\u00a0glaucoma:In patients with\u00a0 angle-closure\u00a0 glaucoma, the immediate\u00a0objective\u00a0of\u00a0treatment\u00a0is\u00a0to\u00a0reopen the angle.\u00a0This\u00a0requires constricting\u00a0the\u00a0pupil. Timolol\u00a0maleate\u00a0has little or\u00a0no effect on the\u00a0pupil.\u00a0Timolol maleateophthalmic solution should\u00a0not be used\u00a0alone\u00a0in the\u00a0treatment\u00a0of angle-closure\u00a0glaucoma.Anaphylaxis:While\u00a0taking beta-blockers,\u00a0patients with a\u00a0history\u00a0 of\u00a0atopy\u00a0or\u00a0a\u00a0history\u00a0 of\u00a0severe\u00a0anaphylactic reactions to\u00a0a\u00a0variety of allergens\u00a0may\u00a0be\u00a0more\u00a0reactive\u00a0to\u00a0repeated\u00a0accidental, diagnostic, or\u00a0 therapeutic challenge with such\u00a0 allergens.\u00a0 Such\u00a0patients may be unresponsive to the\u00a0usual\u00a0 doses\u00a0 of\u00a0 epinephrine\u00a0 used\u00a0to treat\u00a0anaphylactic\u00a0reactions.Muscle\u00a0weakness:Beta-adrenergic\u00a0 blockade has been\u00a0 reported to potentiate muscle\u00a0weakness\u00a0consistent\u00a0with certain\u00a0myasthenic symptoms\u00a0(e.g.,\u00a0diplopia,\u00a0ptosis,\u00a0and\u00a0generalized\u00a0weakness). Timolol has\u00a0 been reported\u00a0rarely to increase muscle weakness\u00a0in\u00a0some\u00a0patients with\u00a0myasthenia\u00a0gravis\u00a0or myasthenic\u00a0symptoms.Information for PatientsPatients\u00a0should\u00a0be instructed\u00a0about\u00a0the\u00a0use of\u00a0preservative-free\u00a0timolol maleateophthalmic solution.Since\u00a0sterility cannot\u00a0be\u00a0 maintained\u00a0 after the individual unit\u00a0 is\u00a0 opened, patients should\u00a0be instructed to use the\u00a0product\u00a0immediately after opening and to\u00a0discard the\u00a0individual\u00a0unit and any remaining\u00a0contents immediately\u00a0after\u00a0use.Patients\u00a0with\u00a0 bronchial\u00a0 asthma, a history of\u00a0 bronchial\u00a0 asthma, severe\u00a0chronic\u00a0obstructive pulmonary\u00a0 disease,\u00a0sinus\u00a0 bradycardia, second\u00a0or\u00a0third\u00a0degree\u00a0atrioventricular\u00a0block,\u00a0 or\u00a0 cardiac\u00a0 failure\u00a0 should\u00a0 be\u00a0 advised not to\u00a0take\u00a0this product(see CONTRAINDICATIONS).Drug InteractionsAlthough\u00a0timolol maleateophthalmic solution used alone has little or no\u00a0effect\u00a0on\u00a0pupil\u00a0size,\u00a0mydriasis\u00a0resulting\u00a0from\u00a0concomitant\u00a0therapy\u00a0with\u00a0timolol maleateophthalmic solution and epinephrine has\u00a0 been reported occasionally.Beta-adrenergic blocking agents:Patients\u00a0who\u00a0 are receiving\u00a0a beta-adrenergic\u00a0 blocking\u00a0agent\u00a0orally\u00a0and preservative-free\u00a0timolol\u00a0 maleateophthalmic solution should\u00a0be observed\u00a0for\u00a0potential\u00a0additive effects of beta-blockade, both systemic\u00a0and on intraocular\u00a0pressure. The\u00a0concomitant\u00a0use of\u00a0two topical beta-adrenergic blocking\u00a0agents\u00a0 is not\u00a0recommended.Calcium antagonists:Caution should\u00a0be used in the\u00a0co-administration\u00a0 of beta-adrenergic\u00a0blocking\u00a0agents,\u00a0such\u00a0as\u00a0preservative-free\u00a0timolol maleateophthalmic solution,\u00a0and\u00a0oral\u00a0or\u00a0intravenous calcium antagonists, because\u00a0 of\u00a0 possible atrioventricular conduction\u00a0disturbances,\u00a0left ventricular failure,\u00a0and hypotension.\u00a0In\u00a0patients with impaired cardiac\u00a0function,\u00a0co-administration should\u00a0 be\u00a0 avoided.Catecholamine-depleting drugs:Close observation\u00a0 of the\u00a0patient is\u00a0 recommended when\u00a0a\u00a0beta-blocker is administered\u00a0to\u00a0patients receiving catecholamine-depleting drugs such\u00a0as reserpine, because\u00a0of possible additive effects and the\u00a0production of hypotension\u00a0and/or marked bradycardia, which may\u00a0result in vertigo,\u00a0syncope,\u00a0 or\u00a0 postural\u00a0hypotension.Digitalis and calciumantagonists:The concomitant\u00a0use\u00a0of beta-adrenergic blocking\u00a0agents with\u00a0digitalis\u00a0 and\u00a0calcium\u00a0antagonists may\u00a0have additive\u00a0 effects\u00a0in prolonging\u00a0atrioventricular\u00a0conduction\u00a0time.CYP2D6inhibitors:Potentiated\u00a0systemic\u00a0beta-blockade\u00a0(e.g.,\u00a0decreased\u00a0heart\u00a0rate,\u00a0depression)\u00a0has been\u00a0reported\u00a0during\u00a0combined\u00a0treatment\u00a0with\u00a0CYP2D6 inhibitors (e.g.,\u00a0quinidine,\u00a0SSRIs)\u00a0and\u00a0timolol.Clonidine:Oral beta-adrenergic blocking\u00a0 agents may\u00a0exacerbate the\u00a0rebound\u00a0hypertension\u00a0which can follow the\u00a0withdrawal of\u00a0 clonidine. There have been no reports\u00a0of exacerbation of rebound\u00a0hypertension with ophthalmic timolol maleate.Injectableepinephrine:(see PRECAUTIONS,General,\u00a0Anaphylaxis)Carcinogenesis, Mutagenesis, Impairment of FertilityIn\u00a0a\u00a0two-year\u00a0study\u00a0of timolol\u00a0maleate\u00a0administered orally to\u00a0rats,\u00a0there was a\u00a0statistically\u00a0significant\u00a0 increase in the incidence\u00a0of adrenal\u00a0 pheochromocytomas\u00a0 in \u00a0male\u00a0rats administered\u00a0300 mg/kg/day\u00a0(approximately\u00a042,000 times\u00a0the\u00a0systemic\u00a0exposure\u00a0following the\u00a0maximum\u00a0recommended human\u00a0ophthalmic\u00a0dose).\u00a0 Similar\u00a0differences\u00a0were not\u00a0observed\u00a0in rats administered oral doses\u00a0equivalent\u00a0to approximately\u00a014,000\u00a0times\u00a0the\u00a0maximum\u00a0recommended human ophthalmic dose.In\u00a0a lifetime oral\u00a0 study\u00a0 in mice, there\u00a0 were statistically significant increases in the\u00a0incidence of benign\u00a0and malignant pulmonary tumors,\u00a0benign uterine polyps and\u00a0mammary\u00a0adenocarcinomas in female\u00a0mice at\u00a0 500 mg/kg/day (approximately 71,000\u00a0times\u00a0the\u00a0systemic exposure following\u00a0the maximum recommended\u00a0 human\u00a0 ophthalmic\u00a0dose), but not\u00a0 at 5\u00a0or\u00a0 50 mg/kg/day\u00a0(approximately\u00a0 700 or\u00a07,000 times,\u00a0respectively,\u00a0the\u00a0systemic\u00a0exposure following\u00a0the maximum recommended human\u00a0 ophthalmic dose). In\u00a0a\u00a0subsequent study in female\u00a0mice,\u00a0in\u00a0 which\u00a0 post-mortem\u00a0 examinations\u00a0 were \u00a0limited to\u00a0the\u00a0uterus and the lungs, a\u00a0statistically significant\u00a0increase in the\u00a0incidence of pulmonary tumors was\u00a0 again\u00a0observed\u00a0 at\u00a0 500 mg/kg/day.The\u00a0increased occurrence\u00a0 of mammary adenocarcinomas\u00a0 was associated with\u00a0elevations in serum prolactin which\u00a0 occurred in female\u00a0mice administered oral\u00a0timolol at\u00a0500 mg/kg/day,\u00a0but not\u00a0 at doses of 5\u00a0or 50 mg/kg/day.\u00a0An\u00a0increased incidence\u00a0 of\u00a0mammary\u00a0adenocarcinomas in rodents\u00a0has\u00a0 been associated with administration of\u00a0several\u00a0other therapeutic agents\u00a0 that\u00a0 elevate serum\u00a0prolactin, but\u00a0no correlation\u00a0between\u00a0serum prolactin\u00a0 levels \u00a0and mammary\u00a0tumors\u00a0has \u00a0been\u00a0 established\u00a0 in\u00a0 humans.\u00a0Furthermore,\u00a0in\u00a0 adult\u00a0 human female subjects who received oral \u00a0dosages of\u00a0up to 60 mg\u00a0of timolol maleate (the\u00a0maximum recommended \u00a0human oral dosage), there\u00a0were\u00a0 no\u00a0clinically\u00a0meaningful \u00a0changes\u00a0 in serum prolactin.Timolol\u00a0maleate was\u00a0 devoid\u00a0 of\u00a0 mutagenic\u00a0 potential\u00a0 when\u00a0 testedinvivo(mouse) in the\u00a0micronucleus\u00a0test and cytogenetic assay\u00a0(doses \u00a0up to 800 mg/kg) andinvitroin\u00a0a\u00a0neoplastic\u00a0cell\u00a0transformation\u00a0assay (up\u00a0to\u00a0100 mcg/mL).\u00a0In\u00a0Ames\u00a0tests\u00a0the\u00a0highest\u00a0concentrations of timolol\u00a0employed, 5,000\u00a0 or 10,000 mcg/plate, were associated \u00a0with\u00a0statistically\u00a0significant elevations of revertants\u00a0observed with\u00a0tester\u00a0strain\u00a0TA100\u00a0(in\u00a0seven\u00a0replicate assays),\u00a0 but not \u00a0in the remaining three\u00a0strains.\u00a0In\u00a0the assays with tester\u00a0strain\u00a0TA100, no consistent dose response relationship\u00a0 was\u00a0 observed, \u00a0and the\u00a0ratio\u00a0of\u00a0test\u00a0to\u00a0control revertants\u00a0did\u00a0 not\u00a0reach\u00a02. A\u00a0ratio\u00a0of\u00a02\u00a0is\u00a0 usually considered the\u00a0criterion\u00a0for\u00a0a\u00a0positive\u00a0Ames\u00a0test.Reproduction and fertility studies in rats demonstrated no adverse effect on\u00a0male\u00a0or\u00a0female\u00a0fertility \u00a0at\u00a0 doses\u00a0up to 21,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human ophthalmic dose.Pregnancy:TeratogenicEffects:Teratogenicity studies\u00a0with timolol\u00a0in mice,\u00a0rats and rabbits\u00a0at oral\u00a0doses up to 50 mg/kg/day\u00a0 (7,000 times\u00a0the\u00a0systemic exposure following the\u00a0maximum\u00a0recommended human\u00a0 ophthalmic\u00a0 dose) demonstrated no\u00a0 evidence\u00a0 of fetal\u00a0malformations.\u00a0Although delayed\u00a0fetal\u00a0ossification\u00a0 was observed at this dose in rats,\u00a0there\u00a0were no\u00a0adverse effects on postnatal development\u00a0of offspring.\u00a0Doses of\u00a01,000\u00a0mg/kg/day\u00a0(142,000 times\u00a0the\u00a0systemic exposure\u00a0 following the maximum recommended\u00a0human\u00a0 ophthalmic\u00a0 dose)\u00a0 were maternotoxic in mice and resulted in an increased\u00a0number\u00a0of\u00a0fetal\u00a0resorptions.\u00a0Increased\u00a0fetal resorptions\u00a0 were\u00a0 also\u00a0 seen\u00a0 in rabbits at\u00a0doses of 14,000\u00a0times\u00a0the\u00a0 systemic exposure following the\u00a0maximum\u00a0recommended\u00a0human ophthalmic\u00a0 dose,\u00a0in this\u00a0case without\u00a0 apparent\u00a0maternotoxicity.There\u00a0are\u00a0 no\u00a0 adequate \u00a0and well-controlled studies in\u00a0 pregnant\u00a0 women. Preservative-free\u00a0timolol maleateophthalmic solution should be used\u00a0during\u00a0pregnancy only\u00a0if the\u00a0potential\u00a0benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.Nursing MothersTimolol\u00a0maleate\u00a0 has\u00a0 been\u00a0 detected\u00a0 in\u00a0 human\u00a0 milk\u00a0 following oral and\u00a0 ophthalmic\u00a0 drug\u00a0administration. Because of the potential\u00a0for serious\u00a0adverse \u00a0reactions from timolol\u00a0in\u00a0nursing\u00a0infants, a decision should\u00a0 be made\u00a0whether to discontinue\u00a0nursing\u00a0 or to\u00a0discontinue the\u00a0drug, taking\u00a0\u00a0 into \u00a0account the\u00a0importance\u00a0 of the drug to the\u00a0mother.Pediatric UseSafety and effectiveness\u00a0of timolol maleate\u00a0ophthalmic solution\u00a0have \u00a0 been established\u00a0when administered in\u00a0pediatric\u00a0 patients aged 2\u00a0years\u00a0and older.\u00a0 Use of\u00a0 timolol\u00a0maleate\u00a0ophthalmic solution\u00a0in these children\u00a0is supported\u00a0 by\u00a0 evidence from adequate\u00a0 and well-controlled studies\u00a0in children and adults.\u00a0Safety and efficacy in\u00a0pediatric patients\u00a0below\u00a0the\u00a0age\u00a0 of 2\u00a0years\u00a0have not \u00a0been\u00a0 established.Geriatric UseNo overall\u00a0 differences\u00a0 in\u00a0 safety\u00a0 or\u00a0 effectiveness \u00a0 have\u00a0 been observed\u00a0 between\u00a0 elderly\u00a0and \u00a0 younger \u00a0patients.",
    "ADVERSE REACTIONS": "The\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.\nThe\u00a0most\u00a0frequently reported adverse\u00a0 experiences\u00a0 have\u00a0 been burning \u00a0and stinging\u00a0upon instillation (approximately\u00a0 one\u00a0 in\u00a0 eight\u00a0 patients).The\u00a0following \u00a0additional\u00a0 adverse\u00a0 experiences have been reported\u00a0less\u00a0 frequently\u00a0 with\u00a0ocular administration of\u00a0this or\u00a0 other timolol maleate formulations:BODY\u00a0AS\u00a0A\u00a0WHOLEHeadache, asthenia/fatigue,\u00a0and chest\u00a0pain.CARDIOVASCULARBradycardia, arrhythmia,\u00a0 hypotension,\u00a0\u00a0 hypertension,\u00a0syncope,\u00a0 heart \u00a0block, cerebral\u00a0vascular\u00a0accident,\u00a0cerebral\u00a0ischemia,\u00a0cardiac\u00a0failure,\u00a0 worsening\u00a0 of\u00a0 angina\u00a0 pectoris,\u00a0palpitation,\u00a0cardiac\u00a0arrest, pulmonary\u00a0edema, edema,\u00a0claudication,\u00a0Raynaud's\u00a0phenomenon, and cold\u00a0hands and feet.DIGESTIVENausea,\u00a0diarrhea, dyspepsia,\u00a0anorexia,\u00a0and dry\u00a0mouth.IMMUNOLOGICSystemic\u00a0lupus\u00a0erythematosus.NERVOUS\u00a0SYSTEM/PSYCHIATRICDizziness, increase\u00a0 in\u00a0 signs\u00a0 and symptoms of myasthenia gravis, paresthesia,\u00a0somnolence, insomnia, nightmares,\u00a0 behavioral changes and\u00a0 psychic\u00a0 disturbances\u00a0including depression, confusion,\u00a0hallucinations,\u00a0 anxiety, disorientation,\u00a0 nervousness,\u00a0and\u00a0memory\u00a0loss.SKINAlopecia\u00a0and\u00a0 psoriasiform\u00a0rash or\u00a0 exacerbation\u00a0 of\u00a0 psoriasis.HYPERSENSITIVITYSigns\u00a0and symptoms\u00a0of systemic\u00a0allergic\u00a0 reactions\u00a0 including anaphylaxis, angioedema,\u00a0urticaria,\u00a0and localized and\u00a0 generalized rash.RESPIRATORYBronchospasm\u00a0(predominantly \u00a0in\u00a0 patients\u00a0 with pre-existing\u00a0bronchospastic disease),\u00a0respiratory failure, dyspnea, nasal\u00a0congestion,\u00a0cough\u00a0 and upper\u00a0respiratory infections.ENDOCRINEMasked\u00a0symptoms\u00a0of hypoglycemia in diabetic patients(see WARNINGS).SPECIAL\u00a0SENSESSigns\u00a0and symptoms of ocular\u00a0irritation\u00a0 including conjunctivitis, blepharitis, keratitis,\u00a0ocular pain, discharge\u00a0(e.g., crusting),\u00a0foreign body sensation,\u00a0itching and tearing,\u00a0and\u00a0dry eyes; ptosis; decreased\u00a0corneal\u00a0sensitivity; cystoid\u00a0macular\u00a0edema;\u00a0visual\u00a0disturbances\u00a0 including refractive changes\u00a0 and\u00a0 diplopia;\u00a0 pseudopemphigoid; choroidal\u00a0detachment\u00a0following\u00a0filtration\u00a0surgery(see PRECAUTIONS,General);\u00a0and\u00a0tinnitus.UROGENITALRetroperitoneal\u00a0fibrosis,\u00a0decreased libido, impotence, and\u00a0Peyronie's\u00a0disease.The\u00a0following additional \u00a0adverse effects have been reported in clinical\u00a0 experience\u00a0with\u00a0ORAL\u00a0timolol\u00a0maleate or\u00a0 other ORAL beta\u00a0 blocking agents, \u00a0and may be\u00a0 considered\u00a0potential\u00a0effects of ophthalmic timolol\u00a0maleate:Allergic: Erythematous\u00a0rash,\u00a0fever\u00a0combined\u00a0with aching\u00a0and sore\u00a0throat,\u00a0laryngospasm\u00a0with respiratory\u00a0distress;Body as\u00a0a\u00a0Whole:\u00a0Extremity\u00a0pain,\u00a0decreased\u00a0exercise\u00a0tolerance,\u00a0weight\u00a0loss;Cardiovascular:\u00a0Worsening\u00a0of\u00a0arterial\u00a0insufficiency,\u00a0vasodilatation;Digestive: Gastrointestinal\u00a0pain,\u00a0 hepatomegaly,\u00a0vomiting, mesenteric arterial\u00a0 thrombosis, \u00a0ischemic colitis;Hematologic:\u00a0Nonthrombocytopenic\u00a0purpura, thrombocytopenic\u00a0 purpura,\u00a0 agranulocytosis;Endocrine:\u00a0Hyperglycemia, hypoglycemia;Skin: Pruritus,\u00a0skin irritation,\u00a0increased\u00a0 pigmentation,\u00a0sweating;Musculoskeletal:\u00a0Arthralgia;Nervous System/Psychiatric:\u00a0Vertigo,\u00a0local\u00a0weakness, diminished\u00a0concentration,\u00a0reversible mental\u00a0depression progressing\u00a0to\u00a0catatonia,\u00a0an acute\u00a0reversible\u00a0syndrome\u00a0characterized\u00a0by\u00a0 disorientation for time\u00a0and\u00a0place,\u00a0emotional lability, slightly\u00a0clouded sensorium, and\u00a0decreased\u00a0 performance\u00a0on\u00a0neuropsychometrics;Respiratory: Rales,\u00a0bronchial\u00a0 obstruction;Urogenital:\u00a0 Urination\u00a0difficulties.To\u00a0report\u00a0SUSPECTED\u00a0ADVERSE\u00a0REACTIONS,\u00a0contact\u00a0Micro Labs USA, Inc. at 1-855-839-8195 or\u00a0FDA\u00a0at\u00a01-800-FDA-1088 orwww.fda.gov/medwatch.",
    "OVERDOSAGE": "There\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.\nThere\u00a0have been reports\u00a0of inadvertent\u00a0overdosage\u00a0with timolol\u00a0maleate\u00a0ophthalmic\u00a0solution\u00a0resulting\u00a0in\u00a0systemic\u00a0effects similar\u00a0to\u00a0those\u00a0seen\u00a0with systemic beta-adrenergic\u00a0blocking\u00a0agents such as dizziness, headache,\u00a0shortness\u00a0of\u00a0 breath,\u00a0bradycardia, bronchospasm,\u00a0 and cardiac\u00a0arrest(see ADVERSE REACTIONS).Overdosage\u00a0has\u00a0 been\u00a0 reported\u00a0with timolol maleate tablets.\u00a0A 30-year-old female\u00a0ingested\u00a0650 mg\u00a0of\u00a0 timolol\u00a0 maleate\u00a0 tablets (maximum recommended\u00a0 oral\u00a0 daily\u00a0 dose is\u00a060 mg) and experienced\u00a0second and third\u00a0degree\u00a0 heart\u00a0 block.\u00a0She\u00a0recovered without\u00a0treatment\u00a0but approximately\u00a0two\u00a0months\u00a0later developed\u00a0 irregular\u00a0 heartbeat,\u00a0hypertension,\u00a0dizziness,\u00a0tinnitus,\u00a0faintness,\u00a0increased\u00a0pulse\u00a0rate,\u00a0and\u00a0borderline\u00a0first\u00a0degree\u00a0 heart \u00a0block.Anin vitrohemodialysis study, using14C\u00a0timolol\u00a0added to\u00a0human plasma\u00a0 or whole\u00a0blood,\u00a0showed that\u00a0timolol\u00a0was readily dialyzed from\u00a0these\u00a0fluids;\u00a0however,\u00a0a\u00a0study\u00a0of\u00a0patients with\u00a0renal failure\u00a0showed that\u00a0timolol did\u00a0not\u00a0 dialyze readily.",
    "DOSAGE AND ADMINISTRATION": "Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).\nPreservative-free\u00a0timolol maleateophthalmic solution is\u00a0a\u00a0sterile\u00a0solution\u00a0that\u00a0does\u00a0not contain\u00a0a\u00a0preservative.\u00a0The\u00a0solution from\u00a0one individual\u00a0 unit is to be used immediately\u00a0 after\u00a0opening for\u00a0administration to\u00a0one or\u00a0 both eyes. Since sterility\u00a0cannot be\u00a0 guaranteed\u00a0after the individual unit is opened, the\u00a0remaining contents\u00a0should\u00a0be\u00a0discarded\u00a0immediately\u00a0after\u00a0administration.Preservative-free\u00a0timolol maleateophthalmic solution is\u00a0available in\u00a0concentration of\u00a00.5%.\u00a0The\u00a0usual starting\u00a0dose is one drop\u00a0of\u00a00.25%\u00a0preservative-free timolol maleateophthalmic solution\u00a0in the\u00a0affected \u00a0eye(s)\u00a0 administered twice\u00a0a day. Apply\u00a0 enough\u00a0 gentle\u00a0pressure on the\u00a0individual\u00a0 container to obtain a\u00a0single\u00a0drop\u00a0of solution.\u00a0If the clinical response\u00a0is\u00a0 not\u00a0 adequate, the dosage may\u00a0be\u00a0 changed to\u00a0one\u00a0 drop \u00a0of 0.5% \u00a0solution \u00a0in\u00a0the affected \u00a0eye(s) \u00a0administered twice\u00a0a day.Since\u00a0in\u00a0some patients\u00a0the\u00a0pressure-lowering\u00a0response\u00a0to\u00a0preservative-free\u00a0timolol maleateophthalmic solution\u00a0may\u00a0require a\u00a0few\u00a0weeks to\u00a0stabilize, evaluation should include a\u00a0determination of intraocular pressure after approximately\u00a04\u00a0weeks of treatment\u00a0with\u00a0preservative-free timolol maleateophthalmic solution.If the intraocular pressure\u00a0is \u00a0maintained at satisfactory levels, the dosage schedule may\u00a0be changed to one \u00a0drop once a day \u00a0in the affected\u00a0 eye(s). Because\u00a0of\u00a0 diurnal variations\u00a0in intraocular pressure, satisfactory\u00a0response to the once-a-day\u00a0dose is \u00a0best determined\u00a0by measuring the intraocular \u00a0pressure \u00a0at\u00a0 different times\u00a0during the \u00a0day.Dosages\u00a0above one drop\u00a0of\u00a00.5%\u00a0timolol\u00a0maleate ophthalmic\u00a0solution\u00a0twice\u00a0a\u00a0day generally\u00a0 have not been shown\u00a0to\u00a0produce\u00a0 further reduction in intraocular\u00a0pressure. \u00a0If the patient's intraocular \u00a0pressure\u00a0 is still not at a\u00a0satisfactory level\u00a0on this\u00a0regimen,\u00a0concomitant therapy with\u00a0other\u00a0 agent(s) for lowering\u00a0intraocular \u00a0pressure\u00a0can\u00a0be instituted taking\u00a0 into consideration\u00a0that\u00a0the preparation(s) used\u00a0 concomitantly may\u00a0contain\u00a0one \u00a0or more preservatives. The\u00a0concomitant use\u00a0 of two\u00a0topical beta-adrenergic\u00a0blocking\u00a0agents is not recommended(see PRECAUTIONS,Drug Interactions,\u00a0Beta-adrenergic blocking agents).",
    "HOW SUPPLIED": "Preservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022\nPreservative-free sterile timolol maleateophthalmic solution, USP is a clear, colorless to\u00a0 light yellow solution.Preservative-free timolol maleateophthalmic solution USP,0.5%timolol equivalent, is supplied in a single-dose vial, clear low density\u00a0 polyethylene\u00a0 unit\u00a0 dose container.\u00a0 Each individual\u00a0 unit contains\u00a0 0.3 mL of solution, and \u00a0is\u00a0 available\u00a0 in a foil laminate\u00a0 overwrapped\u00a0 \u00a0pouch \u00a0as\u00a0 follows:NDC42571-398-71; 0.3 mL single-dose vials in package of 60.StorageStore at room temperature, 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). Protect from freezing. Protect from light.Because evaporation can occur through the unprotected polyethylene\u00a0 unit\u00a0 dose container and prolonged\u00a0 exposure to direct\u00a0 light can modify the product, the unit dose container should be kept in the\u00a0 protective foil overwrap and used\u00a0 within one month after the foil package\u00a0 has \u00a0been\u00a0 opened.Manufactured by:Micro Labs LimitedBangalore-560099, INDIA.Manufactured for:Micro Labs USA, Inc.Somerset, NJ 08873Rev. 06/2022",
    "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL": "Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited\nRx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%Micro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*10\u00d70.3 mL Single-Dose VialsMicro Labs LimitedNDC-42571-398-71Rx onlyTimolol Maleate Ophthalmic Solution, USP 0.5%*60\u00d70.3 mL Single-Dose VialsMicro Labs Limited",
    "INGREDIENTS AND APPEARANCE": "TIMOLOL MALEATE\u00a0\t\t\n\t\t\t\t\t\n\ntimolol maleate solution/ drops\n\n\n\nProduct Information\n\n\nProduct TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42571-398\n\n\nRoute of AdministrationOPHTHALMIC\n\n\n Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42571-398 Route of Administration OPHTHALMIC\nProduct Information\nProduct Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42571-398\nRoute of Administration OPHTHALMIC\n\n\n\nActive Ingredient/Active Moiety\n\n\nIngredient NameBasis of StrengthStrength\n\n\nTIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR) TIMOLOL ANHYDROUS6.8\u00a0mg \u00a0in\u00a01\u00a0mL\n\n\n Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR)  TIMOLOL ANHYDROUS 6.8\u00a0mg \u00a0in\u00a01\u00a0mL\nActive Ingredient/Active Moiety\nIngredient Name Basis of Strength Strength\nTIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR)  TIMOLOL ANHYDROUS 6.8\u00a0mg \u00a0in\u00a01\u00a0mL\n\n\n\nInactive Ingredients\n\n\nIngredient NameStrength\n\n\nSODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO) \u00a0\n\n\nSODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956) \u00a0\n\n\nSODIUM HYDROXIDE (UNII: 55X04QC32I) \u00a0\n\n\nWATER (UNII: 059QF0KO0R) \u00a0\n\n\n Inactive Ingredients Ingredient Name Strength SODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO)  \u00a0 SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  \u00a0 SODIUM HYDROXIDE (UNII: 55X04QC32I)  \u00a0 WATER (UNII: 059QF0KO0R)  \u00a0\nInactive Ingredients\nIngredient Name Strength\nSODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO)  \u00a0\nSODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  \u00a0\nSODIUM HYDROXIDE (UNII: 55X04QC32I)  \u00a0\nWATER (UNII: 059QF0KO0R)  \u00a0\n\n\n\n\nPackaging\n\n\n#Item CodePackage DescriptionMarketing Start DateMarketing End Date\n\n\n1NDC:42571-398-716  in 1 CARTON01/01/2023\n\n\n110  in 1 POUCH\n\n\n10.3 mL in 1 VIAL; Type 0: Not a Combination Product\n\n\n Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:42571-398-71 6  in 1 CARTON 01/01/2023  1  10  in 1 POUCH   1  0.3 mL in 1 VIAL; Type 0: Not a Combination Product  \nPackaging\n# Item Code Package Description Marketing Start Date Marketing End Date\n1 NDC:42571-398-71 6  in 1 CARTON 01/01/2023 \n1  10  in 1 POUCH  \n1  0.3 mL in 1 VIAL; Type 0: Not a Combination Product  \n\n\n\n\nMarketing Information\n\n\nMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date\n\n\nANDAANDA21659601/01/2023\n\n\n Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA216596 01/01/2023 \nMarketing Information\nMarketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date\nANDA ANDA216596 01/01/2023 \nLabeler -\u00a0Micro Labs Limited\n\t\t\t\t\t\t\t(862174955)\n\t\t\t\t\t\t\nEstablishment\nName Address ID/FEI Business Operations\nMicro Labs Limited  677600482 analysis(42571-398) , label(42571-398) , manufacture(42571-398) , pack(42571-398) \nTIMOLOL MALEATE\u00a0\t\t\n\t\t\t\t\t\n\ntimolol maleate solution/ drops\n\n\n\nProduct Information\n\n\nProduct TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42571-398\n\n\nRoute of AdministrationOPHTHALMIC\n\n\n Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42571-398 Route of Administration OPHTHALMIC\nProduct Information\nProduct Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42571-398\nRoute of Administration OPHTHALMIC\n\n\n\nActive Ingredient/Active Moiety\n\n\nIngredient NameBasis of StrengthStrength\n\n\nTIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR) TIMOLOL ANHYDROUS6.8\u00a0mg \u00a0in\u00a01\u00a0mL\n\n\n Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR)  TIMOLOL ANHYDROUS 6.8\u00a0mg \u00a0in\u00a01\u00a0mL\nActive Ingredient/Active Moiety\nIngredient Name Basis of Strength Strength\nTIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR)  TIMOLOL ANHYDROUS 6.8\u00a0mg \u00a0in\u00a01\u00a0mL\n\n\n\nInactive Ingredients\n\n\nIngredient NameStrength\n\n\nSODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO) \u00a0\n\n\nSODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956) \u00a0\n\n\nSODIUM HYDROXIDE (UNII: 55X04QC32I) \u00a0\n\n\nWATER (UNII: 059QF0KO0R) \u00a0\n\n\n Inactive Ingredients Ingredient Name Strength SODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO)  \u00a0 SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  \u00a0 SODIUM HYDROXIDE (UNII: 55X04QC32I)  \u00a0 WATER (UNII: 059QF0KO0R)  \u00a0\nInactive Ingredients\nIngredient Name Strength\nSODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO)  \u00a0\nSODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  \u00a0\nSODIUM HYDROXIDE (UNII: 55X04QC32I)  \u00a0\nWATER (UNII: 059QF0KO0R)  \u00a0\n\n\n\n\nPackaging\n\n\n#Item CodePackage DescriptionMarketing Start DateMarketing End Date\n\n\n1NDC:42571-398-716  in 1 CARTON01/01/2023\n\n\n110  in 1 POUCH\n\n\n10.3 mL in 1 VIAL; Type 0: Not a Combination Product\n\n\n Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:42571-398-71 6  in 1 CARTON 01/01/2023  1  10  in 1 POUCH   1  0.3 mL in 1 VIAL; Type 0: Not a Combination Product  \nPackaging\n# Item Code Package Description Marketing Start Date Marketing End Date\n1 NDC:42571-398-71 6  in 1 CARTON 01/01/2023 \n1  10  in 1 POUCH  \n1  0.3 mL in 1 VIAL; Type 0: Not a Combination Product  \n\n\n\n\nMarketing Information\n\n\nMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date\n\n\nANDAANDA21659601/01/2023\n\n\n Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA216596 01/01/2023 \nMarketing Information\nMarketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date\nANDA ANDA216596 01/01/2023 \nLabeler -\u00a0Micro Labs Limited\n\t\t\t\t\t\t\t(862174955)\n\t\t\t\t\t\t\nEstablishment\nName Address ID/FEI Business Operations\nMicro Labs Limited  677600482 analysis(42571-398) , label(42571-398) , manufacture(42571-398) , pack(42571-398) \nTIMOLOL MALEATE\u00a0\t\t\n\t\t\t\t\t\n\ntimolol maleate solution/ drops\n\n\n\nProduct Information\n\n\nProduct TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42571-398\n\n\nRoute of AdministrationOPHTHALMIC\n\n\n Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42571-398 Route of Administration OPHTHALMIC\nProduct Information\nProduct Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42571-398\nRoute of Administration OPHTHALMIC\n\n\n\nActive Ingredient/Active Moiety\n\n\nIngredient NameBasis of StrengthStrength\n\n\nTIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR) TIMOLOL ANHYDROUS6.8\u00a0mg \u00a0in\u00a01\u00a0mL\n\n\n Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR)  TIMOLOL ANHYDROUS 6.8\u00a0mg \u00a0in\u00a01\u00a0mL\nActive Ingredient/Active Moiety\nIngredient Name Basis of Strength Strength\nTIMOLOL MALEATE (UNII: P8Y54F701R)  (TIMOLOL ANHYDROUS - UNII:5JKY92S7BR)  TIMOLOL ANHYDROUS 6.8\u00a0mg \u00a0in\u00a01\u00a0mL\n\n\n\nInactive Ingredients\n\n\nIngredient NameStrength\n\n\nSODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO) \u00a0\n\n\nSODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956) \u00a0\n\n\nSODIUM HYDROXIDE (UNII: 55X04QC32I) \u00a0\n\n\nWATER (UNII: 059QF0KO0R) \u00a0\n\n\n Inactive Ingredients Ingredient Name Strength SODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO)  \u00a0 SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  \u00a0 SODIUM HYDROXIDE (UNII: 55X04QC32I)  \u00a0 WATER (UNII: 059QF0KO0R)  \u00a0\nInactive Ingredients\nIngredient Name Strength\nSODIUM PHOSPHATE, DIBASIC DODECAHYDRATE (UNII: E1W4N241FO)  \u00a0\nSODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)  \u00a0\nSODIUM HYDROXIDE (UNII: 55X04QC32I)  \u00a0\nWATER (UNII: 059QF0KO0R)  \u00a0\n\n\n\n\nPackaging\n\n\n#Item CodePackage DescriptionMarketing Start DateMarketing End Date\n\n\n1NDC:42571-398-716  in 1 CARTON01/01/2023\n\n\n110  in 1 POUCH\n\n\n10.3 mL in 1 VIAL; Type 0: Not a Combination Product\n\n\n Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:42571-398-71 6  in 1 CARTON 01/01/2023  1  10  in 1 POUCH   1  0.3 mL in 1 VIAL; Type 0: Not a Combination Product  \nPackaging\n# Item Code Package Description Marketing Start Date Marketing End Date\n1 NDC:42571-398-71 6  in 1 CARTON 01/01/2023 \n1  10  in 1 POUCH  \n1  0.3 mL in 1 VIAL; Type 0: Not a Combination Product  \n\n\n\n\nMarketing Information\n\n\nMarketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date\n\n\nANDAANDA21659601/01/2023\n\n\n Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA216596 01/01/2023 \nMarketing Information\nMarketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date\nANDA ANDA216596 01/01/2023 \nLabeler -\u00a0Micro Labs Limited\n\t\t\t\t\t\t\t(862174955)\n\t\t\t\t\t\t\nEstablishment\nName Address ID/FEI Business Operations\nMicro Labs Limited  677600482 analysis(42571-398) , label(42571-398) , manufacture(42571-398) , pack(42571-398) ",
    "product_name": "Timolol Maleate Ophthalmic Solution, USP (Preservative-Free)"
}